Biaryl ether urea compounds
AssigneePfizer Inc.
InventorsLorraine Kathleen Fay, Douglas S. Johnson, Suzanne Ross Kesten, Scott E. Lazerwith, Mark Anthony Morris, Cory Michael Stiff, Marvin Jay Meyers, Lijuan Jane Wang
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing the compounds; and uses of the compounds in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity.
Claims10
A compound of Formula I
- wherein:
- each R1 is independently hydrogen, —OH, halogen, haloalkyl, —C1-C6alkyl, —O—C1-C6alkyl, —S—C1-C6alkyl, aryl, heteroaryl, —O-aryl, —O-heteroaryl, —NH2, —NHC(O)C1-C6alkyl, —(CH2)0-3—C3-C6cycloalkyl, —NHC(O)C3-C6cycloalkyl, —NHC1-C6alkyl, CN, —C(O)NR′R″ or —C(O)C1-C6alkyl;
- with each R1—C1-C6alkyl group being optionally substituted by an —O—C1-C6alkyl group or from 1 to 3 —OH substituents;
- R′ and R″ are independently selected from H or C1-C6alkyl;
- R2 is pyridazine;
- each R3 is independently hydrogen, halogen, haloalkyl, —C1-C6alkyl, —O—C1-C6alkyl, —S—C1-C6alkyl, —(CH2)0-3—C3-C6 cycloalkyl, —S—C3-C6cycloalkyl and —O—C3-C6cycloalkyl;
- said R3—C1-C6alkyl, —O—C1-C6alkyl, —S—C1-C6alkyl, —(CH2)0-3—C3-C6 cycloalkyl, —S—C3-C6cycloalkyl and —O—C3-C6cycloalkyl, groups are optionally substituted with from 1 to 4 halogen, haloalkyl, —O-haloalkyl, —C1-C6alkyl, or —O(C1-C6alkyl) substituents;
- R4 is hydrogen, —C1-C6alkyl, phenyl, —(CH2)0-3—C3-C6 cycloalkyl or halogen;
- said R4—C1-C6alkyl, phenyl, and —(CH2)0-3—C3-C6 cycloalkyl groups being optionally substituted with from 1 to 4 halogen, —C1-C6alkyl, or —O(C1-C6alkyl) substituents;
- X is N or CH;
- m is 0, 1, 2, 3, or 4;
- n is 0, 1, 2, 3 or 4;
- and
- Ar is aryl, —CH2-aryl, or heteroaryl, with said aryl, —CH2-aryl and heteroaryl groups being optionally independently substituted with from 1 to 4 substituents selected from hydrogen, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —(CH2)0-3—C3-C6 cycloalkyl, halogen, haloalkyl, —O-haloalkyl, —C(O)C1-C6alkyl, —O—C1-C6alkyl, —S—C1-C6alkyl, —O—C2-C6alkenyl, —O—C2-C6alkynyl, CN, aryl, heterocyclyl or heteroaryl;
- said —C1-C6alkyl, —(CH2)0-3—C3-C6cycloalkyl, —C(O)C1-C6alkyl, —O(C1-C6alkyl), —S—C1-C6alkyl, aryl, —CH2-aryl, heterocyclyl and heteroaryl substituents on Ar are optionally independently substituted with from 1 to 4 —C1-C6alkyl, —C1-C6alkoxy, —OH, or halogen substituents;
- or a pharmaceutically acceptable salt thereof.
The compound N-pyridazin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising N-pyridazin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.